Ranbaxy sued for handling of atorvastatin recall

Ranbaxy Laboratories' recall of generic Lipitor has spawned its first legal repercussion. A New Jersey man has sued the Indian generics maker, Pharmalot reports, questioning why it took two weeks for the company to publicly notify consumers that they might be getting ground glass with their cholesterol-lowering medicine. The lawsuit points out that even then, there was only a small notice on its U.S. website. The FDA followed up with a national announcement of the voluntary recall of the 41 lots. Ranbaxy has since stopped manufacturing the pills in the affected doses while it figures out whether the discovery of glass in a raw material can be tracked to a missing piece of glass from a machinery shield or some other explanation. Story | More

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.